Aiforia agrees non-binding EIB term sheet for up to €20m venture debt, materially de-risking the fun...
We expect a Q2 characterised by an ongoing transition, including recently announced cost savings, wh...
We foresee strong PFPM/share growth in Q2, up 27% y/y (c.
InCoax has announced a SEK 11.2m directed share issue alongside an expanded credit facility, further...
* Q2e: 13% organic sales growth, 4.5% EBITA margin * We raise opex on increased competition * Tradin...
Cicor announced this morning it is divesting its Tunisian production facility which will close in Ju...
We update our base case after having analysed the ADVANCE data.
Apotea är Sveriges ledande nätapotek med en dominant marknadsposition och fortsatt potential för til...
* Infrea and Netel to merger * The combined company to have ~SEK 5bn in revenue * Stynnergies of ~SE...
Systemair avslutar 2025/26 starkt med hög organisk tillväxt, förbättrad lönsamhet men svagare kvarta...
Xbrane has partnered with California-based CDMO JOINN Biologics to advance CMC development of Xdarza...
Alzinova announced today the successful outcome of the TO4 warrant exercise, completing the bridging...
Gofore May sales were somewhat below our estimate, and day-adjusted organic growth remains in slight...
Magle has announced an update on the ongoing negotiations with its principal bondholders regarding a...
DO & CO closed FY 25/26 with a strong Q4. Sales grew 13% yoy to € 594m and EBIT improved 10% yoy to ...
Yesterday, Bittium received a EUR 14m order from the Finnish Defence Forces for SDR radios to be del...
Redeye reviews BioInvent’s second key opinion leader (KOL) event of 2026, highlighting clinical deve...
Redeye adjusts its forecasts following the FDA's issuance of another complete response letter (CRL) ...
Redeye has raised its forecasts on the back of an upbeat Q4 report.
Redeye updates on Xspray following a management call that provided some clarification on the Nilopki...